Results 111 to 120 of about 6,140 (133)

Strategies to Enhance Protein Delivery. [PDF]

Langmuir
Zhu Y, Zhuang W, Cheng H.
europepmc   +1 more source

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report. [PDF]

Ther Adv Neurol Disord
Kwiedor I, Menacher M, Ellßel M, Naumann M, Bayas A.   +4 more
europepmc   +1 more source

Discovery of three novel neutralizing antibody epitopes on the human astrovirus capsid spike and mechanistic insights into virus neutralization. [PDF]

J Virol
Lanning S, Aguilar-Hernández N, Serrão VHB, López T, O'Rourke SM, Lentz A, Ricemeyer L, Espinosa R, López S, Arias CF, DuBois RM.   +10 more
europepmc   +1 more source

Targeted immunotherapies for Graves' thyroidal & orbital diseases. [PDF]

Front Immunol
Lee ACH, Kahaly GJ.
europepmc   +1 more source

The physiological limits of bispecific monoclonal antibody tissue targeting specificity. [PDF]

MAbs
Sepp A, Stader F, Derbalah A, Liu C, Zyla A, Gardner I, Jamei M.   +6 more
europepmc   +1 more source

Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report. [PDF]

Medicine (Baltimore)
Zhou J, Yu W, Ding S, Shi C, Liang H.
europepmc   +1 more source

Combinatorial Fc modifications for complementary antibody functionality. [PDF]

MAbs
Bartsch YC, Webb NE, Burgess E, Kang J, Lauffenburger DA, Julg BD.   +5 more
europepmc   +1 more source

Wolf in Sheep's Clothing: Taming Cancer's Resistance with Human Serum Albumin? [PDF]

Int J Nanomedicine
Stukan I, Żuk A, Pukacka K, Mierzejewska J, Pawłowski J, Kowalski B, Dąbkowska M.   +6 more
europepmc   +1 more source

PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab. [PDF]

Front Pharmacol
Franz M, Jairam RK, Kuepfer L, Hanke N.
europepmc   +1 more source

Myasthenia gravis: The evolving therapeutic landscape. [PDF]

eNeurologicalSci
Wolfe GI, Hanson JE, Silvestri NJ.
europepmc   +1 more source